Literature DB >> 3134281

Urinary neopterin levels in acute viral hepatitis.

G Reibnegger1, I Auhuber, D Fuchs, A Hausen, G Judmaier, C Prior, E R Werner, H Wachter.   

Abstract

Elevated neopterin levels in blood or urine have been shown to be a marker for the activation of cell-mediated immunity in vitro and in vivo. To evaluate whether neopterin levels are elevated in patients with acute viral hepatitis, we measured urinary levels in 13 patients with hepatitis A, 26 with hepatitis B, 12 with non-A, non-B hepatitis, 8 with jaundice and/or cholestasis due to biliary and pancreatic disorders and 3 with alcoholic hepatitis and in 62 apparently healthy HBsAg carriers. Neopterin levels in patients with virus-induced hepatitis were significantly higher than those in patients with other diagnoses. Urinary neopterin levels were above normal in 49 of 51 patients with viral hepatitis and elevations during the course of hepatitis showed a pattern similar to that of the usual liver biochemical tests, suggesting that neopterin levels were related to the clinical activity of the viral disease. In patients with nonviral biliary and hepatic disorders, neopterin levels were usually normal and did not correlate with other liver biochemical tests. These findings suggest that cell-mediated immune mechanisms are activated during viral hepatitis and that neopterin measurement may be of value as an additional surrogate marker for non-A, non-B hepatitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134281     DOI: 10.1002/hep.1840080412

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  9 in total

1.  Value of urinary neopterin in the differential diagnosis of bacterial and viral infections.

Authors:  H Denz; D Fuchs; A Hausen; H Huber; D Nachbaur; G Reibnegger; J Thaler; E R Werner; H Wachter
Journal:  Klin Wochenschr       Date:  1990-02-15

2.  Serum neopterin levels in children with hepatitis-B-related chronic liver disease and its relationship to disease severity.

Authors:  Enver Mahir Gulcan; Ipek Tirit; Ayse Anil; Erdal Adal; Gulsen Ozbay
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

3.  Response and recovery in the plasma metabolome tracks the acute LCMV-induced immune response.

Authors:  William R Wikoff; Ewa Kalisak; Sunia Trauger; Marianne Manchester; Gary Siuzdak
Journal:  J Proteome Res       Date:  2009-07       Impact factor: 4.466

4.  Serum neopterin concentrations in chronic liver disease.

Authors:  A Wilmer; B Nölchen; H Tilg; M Herold; C Pechlaner; G Judmaier; O Dietze; W Vogel
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

Review 5.  Neopterin in Diagnosis and Monitoring of Infectious Diseases.

Authors:  Michael Eisenhut
Journal:  J Biomark       Date:  2013-12-08

6.  Increased Fecal Neopterin Parallels Gastrointestinal Symptoms in COVID-19.

Authors:  Felix Grabherr; Maria Effenberger; Alisa Pedrini; Lisa Mayr; Julian Schwärzler; Simon Reider; Barbara Enrich; Gernot Fritsche; Sophie Wildner; Rosa Bellmann-Weiler; Günter Weiss; Sabine Scholl-Bürgi; Thomas Müller; Alexander Moschen; Timon E Adolph; Herbert Tilg
Journal:  Clin Transl Gastroenterol       Date:  2021-01-12       Impact factor: 4.396

7.  Serum neopterin levels in relation to mild and severe COVID-19.

Authors:  Josefina Robertson; Johanna M Gostner; Staffan Nilsson; Lars-Magnus Andersson; Dietmar Fuchs; Magnus Gisslen
Journal:  BMC Infect Dis       Date:  2020-12-10       Impact factor: 3.090

Review 8.  The importance of neopterin in COVID-19: The prognostic value and relation with the disease severity.

Authors:  Yousef Rasmi; Nadia Heidari; Kevser Kübra Kırboğa; Shima Hatamkhani; Burcu Tekin; Shahryar Alipour; Roya Naderi; Yeghaneh Farnamian; Ilknur Akca
Journal:  Clin Biochem       Date:  2022-03-17       Impact factor: 3.625

9.  Neopterin and Soluble CD14 Levels as Indicators of Immune Activation in Cases with Indeterminate Pattern and True Positive HIV-1 Infection.

Authors:  Hayriye Kırkoyun Uysal; Pari Sohrabi; Zafer Habip; Suat Saribas; Emre Kocazeybek; Fatih Seyhan; Reyhan Calışkan; Esad Bonabi; Pelin Yuksel; Ilhan Birinci; Omer Uysal; Bekir Kocazeybek
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.